CareMax Updates FY23 Medicare Advantage Membership Guidance To Approximately 110,000 Versus Prior Guidance Of 110,000-120,000; Forecasts Adjusted EBITDA of $15M-$25M Versus Prior Guidance Of $25M-$35M
Portfolio Pulse from Benzinga Newsdesk
CareMax has updated its FY23 Medicare Advantage membership guidance to approximately 110,000, down from the previous guidance of 110,000-120,000. The company also revised its forecast for adjusted EBITDA to $15M-$25M, down from the previous guidance of $25M-$35M.
November 09, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CareMax has lowered its FY23 Medicare Advantage membership and adjusted EBITDA forecasts, which could negatively impact investor sentiment and the company's stock price.
CareMax's downward revision of its FY23 Medicare Advantage membership and adjusted EBITDA forecasts indicates potential challenges in its business operations. This could lead to negative investor sentiment and a potential decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100